arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ANAVEX LIFE SCIENCES CORP.

AVXL
$3.35 ▲ +0.06 (+1.82%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
22 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

ANAVEX LIFE SCIENCES CORP. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $285.7M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -42.8%
FCF / Share $-0.46
Trailing P/E
Price / Book 3.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-46.38M
↓ -7.8%
FCF / Share Free cash flow per share
$-0.46
↓ -24.0%
Long-Term Debt Long-term obligations
$332.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 22 years · 83 quarters